SPRR2C: A Potential Drug Target and Biomarker (G6702)

Target Name: SPRR2C

NCBI ID: G6702

SPRR2C

Other Name(s): small proline-rich protein 2C | Small proline rich protein 2C (pseudogene) | small proline rich protein 2C (pseudogene)

SPRR2C: A Potential Drug Target and Biomarker

Proline-rich proteins (PRPs) are a class of unique proteins that have been identified as potential drug targets in various diseases. PRPs are involved in various cellular processes, including signaling pathways, DNA replication, and stress responses. One of the well-known PRPs is SPRR2C, which has been identified as a potential drug target and biomarker in various diseases.

SPRR2C: Structure and Function

SPRR2C is a protein that belongs to the SPR family, which includes several PRs, including SPR1, SPR2, SPR3, and SPR4. SPRR2C is a small protein that contains 25 amino acid residues. It has a linear molecular structure and a calculated molecular weight of 34 kDa. SPRR2C is expressed in various tissues, including liver, muscle, and heart, and it is also expressed in human placenta, fetal brain, and cancer cells.

SPRR2C functions as a negative regulator of the stress-induced transcriptional repression (SITR) gene. SITR is a non-coding RNA molecule that is involved in the regulation of stress responses in cells. SPRR2C plays a vital role in the regulation of SITR expression by binding to its binding site, which is located on the negative element of the SITR gene.

SPRR2C and SITR: Interaction and Significance

SPRR2C has been shown to interact with SITR, which is a critical protein that regulates the expression of genes involved in stress responses. SPRR2C has been shown to bind to the negative element of the SITR gene with a high affinity, which allows it to inhibit the activity of SITR.

The interaction between SPRR2C and SITR is of great significance, as it provides a potential target for the development of drugs that can alleviate the effects of stress in cells. Studies have shown that SPRR2C is involved in various cellular processes, including stress signaling pathways, DNA replication, and cell growth. Therefore, targeting SPRR2C with drugs that can alleviate stress effects may have potential therapeutic applications in various diseases.

SPRR2C as a Biomarker

SPRR2C has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. SPRR2C has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer. Therefore, using SPRR2C as a biomarker for cancer diagnosis and treatment may have potential applications in the future.

SPRR2C has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that SPRR2C is involved in the regulation of neurotransmitter synthesis and release, which is critical for the function of nerve cells. Therefore, targeting SPRR2C with drugs that can alleviate the effects of neurodegenerative diseases may have potential therapeutic applications in the future.

SPRR2C as a Drug Target

SPRR2C is a small protein that has been shown to have various functions in various cellular processes, including signaling pathways, DNA replication, and stress responses. Therefore, targeting SPRR2C with drugs that can alleviate its effects may have potential therapeutic applications in various diseases.

Targeting SPRR2C with drugs that can alleviate its effects may have potential applications in diseases that are characterized by the over-expression of SPRR2C. For example, SPRR2C has been shown to be involved in the regulation of stress responses, which is critical for the development

Protein Name: Small Proline Rich Protein 2C (pseudogene)

The "SPRR2C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPRR2C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets